Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility
03 août 2023 07h45 HE
|
Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,...
Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health
02 août 2023 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has engaged Research Capital...
Kane Biotech Announces Issuance of Restricted Share Units
23 juin 2023 17h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 9,703,809 restricted share...
Kane Biotech Announces First Quarter 2023 Financial Results
25 mai 2023 16h05 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
25 mai 2023 10h38 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its...
Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow
18 mai 2023 16h05 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results
20 avr. 2023 16h05 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial...
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel
20 avr. 2023 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement...
Kane Biotech Announces Additional coactiv+™ Animal Health Licensing Agreement
18 avr. 2023 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with...
Kane Biotech to Release Fourth Quarter and Full Year 2022 Financial Results on April 20, 2023 – Conference Call to Follow
13 avr. 2023 16h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...